Comparative Study Between CHOP-Like Chemotherapy Plus Rituximab Versus CHOP-Like Chemotherapy Alone in Young Patients With Good Prognosis Diffuse Large-B-Cell Lymphoma

  • Inas Mohamed Ali
  • Sameh Zaki
  • Yasser El-Kerm

Abstract

Background:The role of rituximab in combination with different CHOP
like chemotherapy regimens in young patients with good prognosis diffuse
large B cell lymphoma remains to be defined.

Aim: We aimed to compare CHOP like chemotherapy and rituximab with
CHOP like chemotherapy alone in patients with diffuse large B cell
lymphoma who had no risk factor or one risk factor regarding response,
progression free survival and over all survival as well as toxicity.

Materials and Methods: Eighty patients aged 18-60 years with
histologically confirmed diffuse large B cell lymphoma who had no risk
factor or one risk factor according to the age adjusted international
prognostic index were treated either with: group A treated CHOP
chemotherapy alone, group B treated with CHOP E (CHOP plus
Etoposide), group C treated with CHOP-R (CHOP plus rituximab), group
D treated with CHOP-E-R (CHOP plus Etoposid and retuximab).
Evaluation of response progression free survival over all survival as well as
toxicity.

Results: Patients treated with CHOP rituximab (CHOP-R) had better
response (86%) than those treated with CHOP alone or CHOP plus
etoposide (CHOP E) (83%, 85%) respectively but the difference between
the groups was not statistically significant. There was no statistical
significant difference between the studied groups regarding over all
survival 92% in group B, 93% in group C and 91% in group D.

Conclusions: Rituximab when added to six cycles of CHOP is an effective
treatment for young good prognosis diffuse large B cell lymphoma
however etoposide added to six cycles CHOP is also an effective treatment
for young good prong

Key words: CHOP: Cyclophosphamide, Doxorubicin Vircristine Prednisone
CHOEP: Cyclophosphamide, Doxorubicin Vircristine, Etoposide, Prednisone

Author Biographies

Inas Mohamed Ali
Cancer Management and Research Department, Medical Research Institute, Alexandria University.
Sameh Zaki
Cancer Management and Research Department, Medical Research Institute, Alexandria University.
Yasser El-Kerm
Cancer Management and Research Department, Medical Research Institute, Alexandria University.
Published
2008-12-01
Section
Articles